Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

Rhea-AI Summary

Silo Pharma, Inc. (OTCQB: SILO) announced the engagement of Donohoe Advisory Associates for consulting services related to a potential NASDAQ up-listing. This strategic move aims to enhance visibility and attract a broader investor base. CEO Eric Weisblum emphasized that listing on NASDAQ could increase liquidity for shareholders, although approval and compliance with listing requirements are not guaranteed. Silo Pharma is focused on developing psychedelic therapies for conditions like depression and PTSD, seeking transformative solutions for patients.

Positive

• Engagement of Donohoe Advisory Associates may facilitate NASDAQ up-listing.
• Potential access to a wider base of retail and institutional investors.
• Increased liquidity for shareholders if NASDAQ listing is successful.

Negative

• No guarantee that NASDAQ listing requirements will be met.
• Potential risks and uncertainties associated with forward-looking statements.

Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC ("Donohoe") for consulting and advisory services in connection with the potential up-listing of Silo’s common shares on the NASDAQ Stock Market.

Silo Pharma hopes to gain additional exposure and access to a wider base of retail and institutional investors in the United States and abroad by up-listing to NASDAQ.  The listing of Silo’s common shares on NASDAQ is subject to the approval of that exchange and the satisfaction of all applicable listing requirements. There can be no guarantee that the NASDAQ requirements will be met.

Silo Pharma’s CEO Eric Weisblum, stated, “NASDAQ would provide the Company with a considerably higher profile and the potential for increased liquidity for our shareholders.”

About Donohoe Advisory

Founded in 2004 by David A. Donohoe, Jr., former Chief Counsel for the Listing Qualifications Department of The Nasdaq Stock Market, Donohoe Advisory Associates assists companies which seek to go public and get listed as well with structuring financing and acquisition transactions. Since 2004, Donohoe Advisory has advised well over 1,000 companies and law firms in listing related engagements. For more information, please visit: https://www.donohoeadvisory.com/.

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com

FAQ

What is the significance of Silo Pharma's engagement with Donohoe Advisory Associates?

The engagement is aimed at facilitating Silo Pharma's potential up-listing on the NASDAQ, which could enhance visibility and attract more investors.

What are the potential benefits of Silo Pharma up-listing on NASDAQ?

Up-listing could provide increased liquidity for shareholders and access to a broader investor base.

What challenges does Silo Pharma face in up-listing to NASDAQ?

The main challenge is meeting all the NASDAQ listing requirements, as there is no guarantee these will be satisfied.

What therapeutic areas does Silo Pharma focus on?

Silo Pharma focuses on using psychedelics as therapies for conditions such as depression, PTSD, Alzheimer's, and other neurological disorders.

What does the future hold for Silo Pharma regarding its NASDAQ up-listing?

The future will depend on meeting the necessary listing requirements and addressing associated risks outlined in the company's forward-looking statements.